Can-Fite BioPharma annual net debt
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma Net Debt Growth & History (CANF)
Can-Fite BioPharma's net debt was −$5.5M for fiscal 2025.
View full Can-Fite BioPharma company overviewCan-Fite BioPharma annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$5.5M | −$736,000 | — |
| 2024 | 2024-12-31 | −$4.7M | −$483,000 | — |
| 2023 | 2023-12-31 | −$4.2M | −$1.3M | — |
| 2022 | 2022-12-31 | −$2.9M | $1.4M | — |
| 2021 | 2021-12-31 | −$4.3M | $3.9M | — |
| 2020 | 2020-12-31 | −$8.2M | −$5.7M | — |
| 2019 | 2019-12-31 | −$2.5M | — | — |
Can-Fite BioPharma quarterly net debt
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$5.5M | −$736,000 | — |
| Q2 2025 | 2025-06-30 | −$6.4M | −$1.7M | — |
| Q4 2024 | 2024-12-31 | −$4.7M | −$483,000 | — |
| Q2 2024 | 2024-06-30 | −$4.7M | −$1.3M | — |
| Q4 2023 | 2023-12-31 | −$4.2M | −$1.3M | — |
| Q2 2023 | 2023-06-30 | −$3.4M | −$1.8M | — |
| Q4 2022 | 2022-12-31 | −$2.9M | $1.4M | — |
| Q2 2022 | 2022-06-30 | −$1.6M | $5.8M | — |
| Q4 2021 | 2021-12-31 | −$4.3M | $3.9M | — |
| Q2 2021 | 2021-06-30 | −$7.5M | $1.5M | — |
| Q4 2020 | 2020-12-31 | −$8.2M | −$5.7M | — |
| Q2 2020 | 2020-06-30 | −$9.0M | — | — |
| Q4 2019 | 2019-12-31 | −$2.5M | — | — |
Can-Fite BioPharma net debt trends
Over the last five fiscal years, Can-Fite BioPharma's net debt increased from −$8.2M to −$5.5M, a change of $2.7M. The latest reported quarter, Q4 2025, shows −$5.5M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Can-Fite BioPharma source filings ↗